Clinical trials: Chronic Renal Disease
Cognitive Impairment, End Stage Renal Disease
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
This study will evaluate the tolerability, feasibility, and efficacy of the AKST1210 column in subjects with end-stage renal disease with cognitive impairment (ESRD-CI) undergoing hemodialysis 3 times per week.
- Trial name
- NCT04527328
- Testing
- AKST1210, Hemodialysis
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alkahest, Inc.
End Stage Renal Disease
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
It is intended to examine the safety and efficacy of desensitization therapy by GB-0998 (intravenous immunoglobulin) for the anti-donor antibody positive recipient in need of pre-transplant desensitization.
- Trial name
- NCT02032095
- Testing
- GB-0998
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Japan Blood Products Organization
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
This is an observational study in which data from people with chronic kidney disease (CKD) and Type 2 diabetes mellitus (T2D) are collected and studied.
- Trial name
- 22663 (NCT06608212)
- Testing
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Where
- United States
- Volunteers
- 238,038 people
- Sponsor
- Bayer
Chronic Kidney Disease Stage 3, Anemia
Desidustat in the Treatment of Anemia in CKD
This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who…
- Conditions
- Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
- Trial name
- DREAM-ND (NCT04012957)
- Testing
- Desidustat Oral Tablet, Darbepoetin Alfa
- Where
- 32 sites in India
- Volunteers
- 588 people
- Sponsor
- Zydus Lifesciences Limited
Chronic Kidney Failure
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients
A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been generally called "Enteric DialysisTM".
- Trial name
- NCT01450657
- Testing
- Kibow Biotics/Renadyl
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kibow Pharma
Hyperphosphatemia, ESRD
Phosphate Kinetic Modeling 2
The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population.
- Trial name
- PKM2 (NCT01252771)
- Testing
- PKM Algorithm
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Disease
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan.
- Trial name
- NCT04991571
- Testing
- Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease.
- Trial name
- NCT06077864
- Testing
- survodutide
- Where
- 542 sites in United States, Argentina and 33 more
- Volunteers
- 5,530 people
- Sponsor
- Boehringer Ingelheim
Anemia
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
This observational, prospective, multi-centre, single-arm study will evaluate the efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic kidney disease previously on treatment with short-acting…
- Trial name
- NCT01417377
- Testing
- Mircera
- Where
- 6 sites in Pakistan
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease
Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment
Primary Objective: To assess the tolerability and safety of repeated oral ascending doses of SAR407899A in patients with moderate chronic kidney disease (CKD) on stable angiotensin converting enzyme-inhibitor (ACE-I) Secondary…
- Trial name
- NCT01485900
- Testing
- SAR407899A
- Where
- 2 sites in Moldova, Romania
- Volunteers
- 20 people
- Sponsor
- Sanofi
End Stage Renal Disease, ESRD
Early Feasibility Study to Evaluate the Safety and Efficacy of PAK HD in ESRD Patients
The purpose of this study is to demonstrate the safety of dialysate regeneration of the PAK HD sorbent cartridge and therapy efficacy of the PAK HD sorbent therapy compared with conventional hemodialysis.
- Trial name
- NCT06433193
- Testing
- PAK HD Sorbent Therapy
- Where
- Singapore
- Volunteers
- 3 people
- Sponsor
- Nextkidney S.A.
Arterio-Venous Fistula, Kidney Failure, Chronic
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
This is a prospective single arm study enrolling patients who are scheduled for creation of a new Brachiocephalic or Radiocephalic AV fistula.
- Conditions
- Arterio-Venous Fistula, Kidney Failure, Chronic, Kidney Diseases, Renal Failure Chronic
- Trial name
- VALUE (NCT03246984)
- Testing
- VasQ
- Where
- 11 sites in France, Germany and 2 more
- Volunteers
- 80 people
- Sponsor
- Laminate Medical Technologies
Renal Failure Chronic
Immunotherapy of Chronic Kidney Failure
Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self.
- Trial name
- NCT04377243
- Testing
- V8
- Where
- Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Kidney Disease, Chronic
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta).
- Trial name
- NCT02263833
- Testing
- Mircera
- Where
- South Korea
- Volunteers
- 748 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease
RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients
The overall study objective is to collect real-world data on the safety and effectiveness of ERC to gradually increase 25D to the level required by Stage 3 and 4 CKD patients.
- Trial name
- PORTRAY (NCT05460234)
- Where
- 16 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Vifor (International) Inc.
End-stage Renal Disease
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
A prospective, single arm, non-randomized pivotal study to evaluate the safety and performance of the Xeltis hemodialysis access graft in subjects older than 18 years with end-stage renal disease, who plan to undergo hemodialysis…
- Trial name
- NCT05473299
- Testing
- Xeltis Hemodialysis Access (aXess) graft
- Where
- 22 sites in Belgium, Germany and 7 more
- Volunteers
- 120 people
- Sponsor
- Xeltis
Chronic Kidney Diseases
Chronic Kidney Disease Registry Platform Study
This is a multicenter, prospective, observational registry platform study which is designed to establish a CKD registry platform by collecting data on the demographics, etiology and staging, clinical characteristics, diagnostic…
- Trial name
- NCT06117852
- Where
- 34 sites in China
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca
Anemia, Chronic Renal Insufficiency
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
This is a randomized, controlled, double-blind, multicenter multinational safety study involving about 300 predialysis patients aged 18 years or above suffering from anemia. Symptomatic anemia will be corrected by s.c.
- Trial name
- NCT00701714
- Testing
- HX575 recombinant human erythropoietin alfa, ERYPO
- Where
- 123 sites in Austria, Bulgaria and 8 more
- Volunteers
- 337 people
- Sponsor
- Sandoz
Anemia, Kidney Disease, Chronic
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis
This comparative, open-label, multicenter, parallel-group study evaluated the effect of altitude on the dose requirements of Mircera (methoxy polyethylene glycol-epoetin beta) to achieve a target hemoglobin concentration of 11-12…
- Trial name
- ALTITUD (NCT01519947)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 7 sites in Mexico
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Hypertension
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone.
- Conditions
- Chronic Kidney Disease, Hypertension, Hyperkalemia
- Trial name
- AMETHYST-DN (NCT01371747)
- Testing
- patiromer, losartan, spironolactone
- Where
- 43 sites in Croatia, Georgia and 3 more
- Volunteers
- 324 people
- Sponsor
- Relypsa, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.